Titan Pharmaceuticals Announces Positive Results of Six-Month Open-Label Safety Retreatment Study of Probuphine

News   Feb 09, 2012

 
Titan Pharmaceuticals Announces Positive Results of Six-Month Open-Label Safety Retreatment Study of Probuphine
 
 
 

RELATED ARTICLES

BIA Separations appoints Pete Gagnon as Chief Scientific Officer

News

Appointment will drive new product and applications development.

READ MORE

Heart-on-a-chip Manufactured More Efficiently to Speed Up Drug Testing

News

Testing new clinical drugs' effect on heart tissue could become quicker and more straightforward, thanks to new research from Harvard University.

The study, sets out a new, faster method for manufacturing a 'heart-on-a-chip', which can be used to test the reaction of heart tissue to external stimuli.

READ MORE

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE